Celularity, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$7.9M
Doctors Paid
1,208
Transactions
3,545
2022 Total
$1.9M
Payment Breakdown by Category
Research$4.1M (51.8%)
Consulting$2.4M (30.4%)
Food & Beverage$74,919 (0.9%)
Travel$51,827 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.1M | 138 | 51.8% |
| Consulting Fee | $2.4M | 251 | 30.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $927,050 | 1,537 | 11.7% |
| Current or prospective ownership or investment interest | $337,500 | 3 | 4.3% |
| Food and Beverage | $74,919 | 1,509 | 0.9% |
| Travel and Lodging | $51,827 | 103 | 0.7% |
| Grant | $16,000 | 3 | 0.2% |
| Gift | $3,131 | 1 | 0.0% |
Payments by Type
Research
$4.1M
137 transactions
General
$3.8M
3,407 transactions
Ownership
$0
1 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) With or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults With Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission With Minimal Residual Disease (MRD) or Relapsed/Refractory (R/R) AML | $752,516 | 0 | 14 |
| Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) in Adults With Primary or Secondary AML in Morphologic Complete Remission With Minimal Residual Disease | $668,215 | 0 | 14 |
| A phase 1 multicenter open label safety study of human cord blood derived culture expanded natural killer cell (PNK 007) infusion following autologous stem cell transplant for multiple myeloma | $456,584 | 0 | 28 |
| A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) in Adults With Recurrent Glioblastoma Multiforme (GBM) | $338,120 | 0 | 3 |
| A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting | $315,629 | 0 | 10 |
| A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19 | $253,708 | 0 | 9 |
| A Phase I II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting. | $228,079 | 0 | 9 |
| A single arm study to assess the safety of transplantation with human placental derived stem cells combined with unrelated and related cord blood in Study subjects with certain malignant hematologic diseases and non malignant disorders | $221,581 | 0 | 4 |
| A Phase I II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19 | $217,140 | 0 | 9 |
| A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting. | $158,159 | 0 | 8 |
| A Phase I/IIa Open Label Multicenter, Non-Randomized, Trial to Assess the Safety and Efficacy of CYNK-001in Combination With Recombinant Human Interleukin-2 in Adults With Recurrent Resection Eligible IDH1 Wild-type Glioblastoma | $128,571 | 0 | 4 |
| A Single-Arm Study to Assess the Safety of Transplantation with Human Placental Derived Stem Cells Combined with Unrelated and Related Cord Blood in Study Subjects with Certain Malignant Hematologic Diseases and Non-Malignant Disorders | $101,219 | 0 | 1 |
| Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease | $66,740 | 0 | 17 |
| A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM) | $28,779 | 0 | 5 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. Andrew Pecora, Md, MD | Hematology | Hackensack, NJ | $1.3M | $0 |
| Andrew Von Eschenbach, Md, MD | Urology | Montgomery, TX | $379,843 | $0 |
| Robin Smith, Md, MD | Urology | New York, NY | $212,526 | $0 |
| Yelena Yeretsky, Do, DO | Dermatology | Belleville, NJ | $194,500 | $0 |
| Dr. Nancy Sapanara, Md, MD | Anatomic Pathology & Clinical Pathology | Darby, PA | $91,000 | $0 |
| Dr. Darren Sigal, Md, MD | Medical Oncology | La Jolla, CA | $81,019 | $0 |
| Susan Pitman, Md, MD | Obstetrics & Gynecology | West Orange, NJ | $76,700 | $0 |
| Dr. Kirk Mccullough, Md, MD | Foot and Ankle Surgery | Leawood, KS | $63,868 | $0 |
| Dr. Stephen Brigido, D.p.m, D.P.M | Foot & Ankle Surgery | Bethlehem, PA | $52,893 | $0 |
| Donald Mrdjenovich, Dpm, DPM | Podiatrist | Altoona, PA | $36,603 | $0 |
| Alan Leahey, Md, MD | Ophthalmology | Greenville, SC | $35,238 | $0 |
| Anuj Chopra, Md, MD | Urology | New Hartford, NY | $34,428 | $0 |
| Dr. Gary Stone, Md, MD | Anatomic Pathology & Clinical Pathology | Huntington, NY | $33,813 | $0 |
| Dr. Matthew Iammatteo, M.d, M.D | Specialist | Morristown, NJ | $25,796 | $0 |
| Dr. Christopher Corwin, Dpm, DPM | Podiatrist | Johns Creek, GA | $16,444 | $0 |
| Dr. Mitchell Cairo, Md, MD | Pediatric Hematology-Oncology | Hawthorne, NY | $15,069 | $0 |
| Jeremy Christensen, D.p.m, D.P.M | Podiatrist | Castle Rock, CO | $12,855 | $0 |
| Dr. Mohamad Hussein, M.d, M.D | Internal Medicine | Tampa, FL | $12,300 | $0 |
| Craig Bissinger, Md, MD | Obstetrics & Gynecology | Parsippany, NJ | $9,606 | $0 |
| Aaron Haire, Dpm, DPM | Foot & Ankle Surgery | West Columbia, SC | $8,799 | $0 |
| Vanessa Valarezo, M.d, M.D | Obstetrics & Gynecology | Parsippany, NJ | $8,656 | $0 |
| Dr. Jennifer Greene, M.d, M.D | Obstetrics & Gynecology | Wayne, NJ | $7,500 | $0 |
| Mark Hofbauer, Dpm, DPM | Podiatrist | Belle Vernon, PA | $7,406 | $0 |
| Sharon Mass, Md, MD | Obstetrics & Gynecology | Morristown, NJ | $7,337 | $0 |
| Anish Shah, Md, MD | Ophthalmology | Norwich, CT | $7,301 | $0 |
About Celularity, Inc.
Celularity, Inc. has made $7.9M in payments to 1,208 healthcare providers, recorded across 3,545 transactions in the CMS Open Payments database. In 2022, the company paid $1.9M. The top product by payment volume is Biovance ($227,094).
Payments were distributed across 77 medical specialties. The top specialty by payment amount is Hematology ($1.3M to 4 doctors).
Payment categories include: Food & Beverage ($74,919), Consulting ($2.4M), Research ($4.1M), Travel & Lodging ($51,827).
Celularity, Inc. is associated with 3 products in the CMS Open Payments database.